Welcome to Oncoparse.
We are redefining the future of pancreatic cancer diagnosis and treatment.
About Us
-
"To change the landscape of pancreatic cancer diagnostics by providing reliable, rapid, and actionable insights for better patient care."
At Oncoparse, we are driven by a singular mission: to make pancreatic cancer a manageable condition. This aggressive disease has historically had one of the lowest survival rates, primarily due to late diagnosis and limited treatment options. Our goal is to develop a diagnostic solution that supports clinicians in the fight against pancreatic cancer, ultimately enhancing survival rates and quality of life for patients. -
A world where pancreatic cancer is detected early and managed effectively, enabling patients to live longer, healthier lives.
-
We are developing a non-invasive diagnostic tool that leverages circulating tumor DNA (ctDNA) and advanced sequencing technologies. Our proprietary algorithms will allow us to deliver comprehensive genetic and epigenetic insights, making personalised treatment decisions possible.
Oncoparse is pioneering a next-generation diagnostic tool focused on transforming pancreatic cancer care. With cutting-edge liquid biopsy technology and advanced data analysis, we aim to deliver precise and timely insights that empower clinicians to make informed treatment decisions, improve patient outcomes, and bring hope to those affected by one of the most challenging cancers.
Drop us a line
Whether you’re a patient, clinician, researcher, or investor, we’d love to connect with you. Reach out to learn more about current opportunities.